nodes	percent_of_prediction	percent_of_DWPC	metapath
Mesalazine—Aminosalicylic Acids—Sulfasalazine—ankylosing spondylitis	0.403	1	CiPCiCtD
Mesalazine—Crohn's disease—ankylosing spondylitis	0.148	0.585	CtDrD
Mesalazine—Olsalazine—Sulfasalazine—ankylosing spondylitis	0.119	1	CrCrCtD
Mesalazine—ulcerative colitis—ankylosing spondylitis	0.105	0.415	CtDrD
Mesalazine—CHUK—Sulfasalazine—ankylosing spondylitis	0.0644	0.345	CbGbCtD
Mesalazine—IKBKB—Sulfasalazine—ankylosing spondylitis	0.0465	0.25	CbGbCtD
Mesalazine—ALOX5—Sulfasalazine—ankylosing spondylitis	0.0251	0.135	CbGbCtD
Mesalazine—PPARG—Sulfasalazine—ankylosing spondylitis	0.0224	0.12	CbGbCtD
Mesalazine—PTGS2—Sulfasalazine—ankylosing spondylitis	0.00667	0.0358	CbGbCtD
Mesalazine—PTGS2—Triamcinolone—ankylosing spondylitis	0.00667	0.0358	CbGbCtD
Mesalazine—PTGS2—Betamethasone—ankylosing spondylitis	0.00573	0.0307	CbGbCtD
Mesalazine—PTGS1—Sulfasalazine—ankylosing spondylitis	0.00564	0.0302	CbGbCtD
Mesalazine—PTGS2—Dexamethasone—ankylosing spondylitis	0.00333	0.0179	CbGbCtD
Mesalazine—MPO—IL23-mediated signaling events—IL23R—ankylosing spondylitis	0.000967	0.0559	CbGpPWpGaD
Mesalazine—CHUK—IL1-mediated signaling events—IL1R2—ankylosing spondylitis	0.000453	0.0262	CbGpPWpGaD
Mesalazine—CHUK—NOD1/2 Signaling Pathway—CARD9—ankylosing spondylitis	0.000423	0.0245	CbGpPWpGaD
Mesalazine—IKBKB—IL1-mediated signaling events—IL1R2—ankylosing spondylitis	0.000411	0.0238	CbGpPWpGaD
Mesalazine—CHUK—Interleukin-1 signaling—IL1R2—ankylosing spondylitis	0.000398	0.023	CbGpPWpGaD
Mesalazine—MPO—IL23-mediated signaling events—IL17A—ankylosing spondylitis	0.000385	0.0223	CbGpPWpGaD
Mesalazine—IKBKB—NOD1/2 Signaling Pathway—CARD9—ankylosing spondylitis	0.000384	0.0222	CbGpPWpGaD
Mesalazine—IKBKB—Interleukin-1 signaling—IL1R2—ankylosing spondylitis	0.000361	0.0209	CbGpPWpGaD
Mesalazine—MPO—IL23-mediated signaling events—IL12B—ankylosing spondylitis	0.000358	0.0207	CbGpPWpGaD
Mesalazine—CHUK—NOD pathway—CARD9—ankylosing spondylitis	0.000338	0.0196	CbGpPWpGaD
Mesalazine—IKBKB—NOD pathway—CARD9—ankylosing spondylitis	0.000307	0.0177	CbGpPWpGaD
Mesalazine—CHUK—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—CARD9—ankylosing spondylitis	0.000289	0.0167	CbGpPWpGaD
Mesalazine—IKBKB—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—CARD9—ankylosing spondylitis	0.000262	0.0151	CbGpPWpGaD
Mesalazine—IKBKB—IL17 signaling pathway—IL17A—ankylosing spondylitis	0.00022	0.0127	CbGpPWpGaD
Mesalazine—CHUK—IL1-mediated signaling events—IL1RN—ankylosing spondylitis	0.000214	0.0124	CbGpPWpGaD
Mesalazine—CHUK—TNF receptor signaling pathway —TNFRSF1B—ankylosing spondylitis	0.000199	0.0115	CbGpPWpGaD
Mesalazine—IKBKB—IL1-mediated signaling events—IL1RN—ankylosing spondylitis	0.000194	0.0112	CbGpPWpGaD
Mesalazine—PTGS1—Prostaglandin Synthesis and Regulation—PTGER4—ankylosing spondylitis	0.000189	0.0109	CbGpPWpGaD
Mesalazine—CHUK—Interleukin-1 signaling—IL1RN—ankylosing spondylitis	0.000188	0.0109	CbGpPWpGaD
Mesalazine—IKBKB—Apoptosis Modulation and Signaling—IL1R2—ankylosing spondylitis	0.000187	0.0108	CbGpPWpGaD
Mesalazine—IKBKB—TNF receptor signaling pathway —TNFRSF1B—ankylosing spondylitis	0.00018	0.0104	CbGpPWpGaD
Mesalazine—CHUK—Signaling by Interleukins—IL1R2—ankylosing spondylitis	0.00018	0.0104	CbGpPWpGaD
Mesalazine—IKBKB—Interleukin-1 signaling—IL1RN—ankylosing spondylitis	0.000171	0.00987	CbGpPWpGaD
Mesalazine—MPO—Vitamin B12 Metabolism—CRP—ankylosing spondylitis	0.00017	0.00984	CbGpPWpGaD
Mesalazine—CHUK—Endogenous TLR signaling—TLR4—ankylosing spondylitis	0.000163	0.00945	CbGpPWpGaD
Mesalazine—CHUK—IKK complex recruitment mediated by RIP1—TLR4—ankylosing spondylitis	0.000163	0.00945	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by Interleukins—IL1R2—ankylosing spondylitis	0.000163	0.00943	CbGpPWpGaD
Mesalazine—CHUK—IL1-mediated signaling events—IL1A—ankylosing spondylitis	0.000154	0.00893	CbGpPWpGaD
Mesalazine—PTGS1—Overview of nanoparticle effects—CRP—ankylosing spondylitis	0.000153	0.00887	CbGpPWpGaD
Mesalazine—PTGS2—Prostaglandin Synthesis and Regulation—PTGER4—ankylosing spondylitis	0.00015	0.00868	CbGpPWpGaD
Mesalazine—IKBKB—Endogenous TLR signaling—TLR4—ankylosing spondylitis	0.000148	0.00857	CbGpPWpGaD
Mesalazine—IKBKB—IKK complex recruitment mediated by RIP1—TLR4—ankylosing spondylitis	0.000148	0.00857	CbGpPWpGaD
Mesalazine—IKBKB—IL1-mediated signaling events—IL1A—ankylosing spondylitis	0.00014	0.00809	CbGpPWpGaD
Mesalazine—MPO—Folate Metabolism—CRP—ankylosing spondylitis	0.000138	0.008	CbGpPWpGaD
Mesalazine—CHUK—Interleukin-1 signaling—IL1A—ankylosing spondylitis	0.000136	0.00784	CbGpPWpGaD
Mesalazine—IKBKB—Interleukin-1 signaling—IL1A—ankylosing spondylitis	0.000123	0.00711	CbGpPWpGaD
Mesalazine—CHUK—Apoptosis—TNFRSF1B—ankylosing spondylitis	0.000123	0.00711	CbGpPWpGaD
Mesalazine—PTGS2—Overview of nanoparticle effects—CRP—ankylosing spondylitis	0.000122	0.00704	CbGpPWpGaD
Mesalazine—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—ankylosing spondylitis	0.00012	0.00694	CbGpPWpGaD
Mesalazine—CHUK—Structural Pathway of Interleukin 1 (IL-1)—IL1A—ankylosing spondylitis	0.000119	0.00689	CbGpPWpGaD
Mesalazine—PTGS2—Fluocinonide—Methylprednisolone—ankylosing spondylitis	0.000119	0.159	CbGdCrCtD
Mesalazine—PTGS2—Fluocinonide—Dexamethasone—ankylosing spondylitis	0.000117	0.156	CbGdCrCtD
Mesalazine—PTGS2—Fluocinonide—Betamethasone—ankylosing spondylitis	0.000117	0.156	CbGdCrCtD
Mesalazine—IKBKB—MAPK Signaling Pathway—IL1R2—ankylosing spondylitis	0.000115	0.00662	CbGpPWpGaD
Mesalazine—PTGS2—Fluocinonide—Triamcinolone—ankylosing spondylitis	0.000114	0.153	CbGdCrCtD
Mesalazine—CHUK—TNF alpha Signaling Pathway—TNFRSF1B—ankylosing spondylitis	0.000114	0.00661	CbGpPWpGaD
Mesalazine—CHUK—Leptin signaling pathway—IL1RN—ankylosing spondylitis	0.000114	0.00659	CbGpPWpGaD
Mesalazine—IKBKB—Apoptosis—TNFRSF1B—ankylosing spondylitis	0.000111	0.00644	CbGpPWpGaD
Mesalazine—MPO—Selenium Micronutrient Network—CRP—ankylosing spondylitis	0.00011	0.00636	CbGpPWpGaD
Mesalazine—CHUK—BCR signaling pathway—CD79A—ankylosing spondylitis	0.000109	0.00633	CbGpPWpGaD
Mesalazine—IKBKB—Structural Pathway of Interleukin 1 (IL-1)—IL1A—ankylosing spondylitis	0.000108	0.00625	CbGpPWpGaD
Mesalazine—CHUK—IL-1 signaling pathway—IL1A—ankylosing spondylitis	0.000105	0.00608	CbGpPWpGaD
Mesalazine—IKBKB—Apoptosis Modulation and Signaling—TNFRSF1B—ankylosing spondylitis	0.000105	0.00604	CbGpPWpGaD
Mesalazine—ALOX5—Selenium Micronutrient Network—CRP—ankylosing spondylitis	0.000104	0.006	CbGpPWpGaD
Mesalazine—CHUK—TCR Signaling Pathway—IL17A—ankylosing spondylitis	0.000104	0.00599	CbGpPWpGaD
Mesalazine—IKBKB—TNF alpha Signaling Pathway—TNFRSF1B—ankylosing spondylitis	0.000104	0.00599	CbGpPWpGaD
Mesalazine—IKBKB—Leptin signaling pathway—IL1RN—ankylosing spondylitis	0.000103	0.00597	CbGpPWpGaD
Mesalazine—PTGS2—Calcium signaling in the CD4+ TCR pathway—CD40LG—ankylosing spondylitis	0.000103	0.00597	CbGpPWpGaD
Mesalazine—MPO—IL23-mediated signaling events—TNF—ankylosing spondylitis	9.95e-05	0.00576	CbGpPWpGaD
Mesalazine—IKBKB—BCR signaling pathway—CD79A—ankylosing spondylitis	9.92e-05	0.00574	CbGpPWpGaD
Mesalazine—IKBKB—IL-1 signaling pathway—IL1A—ankylosing spondylitis	9.53e-05	0.00551	CbGpPWpGaD
Mesalazine—CHUK—TCR signaling in naïve CD8+ T cells—HLA-A—ankylosing spondylitis	9.48e-05	0.00548	CbGpPWpGaD
Mesalazine—IKBKB—TCR Signaling Pathway—IL17A—ankylosing spondylitis	9.4e-05	0.00543	CbGpPWpGaD
Mesalazine—CHUK—p75(NTR)-mediated signaling—MMP3—ankylosing spondylitis	9.27e-05	0.00536	CbGpPWpGaD
Mesalazine—PPARG—Transcription factor regulation in adipogenesis—TNF—ankylosing spondylitis	8.81e-05	0.0051	CbGpPWpGaD
Mesalazine—CHUK—Toll-like Receptor Signaling Pathway—IL12B—ankylosing spondylitis	8.72e-05	0.00504	CbGpPWpGaD
Mesalazine—IKBKB—TCR signaling in naïve CD8+ T cells—HLA-A—ankylosing spondylitis	8.6e-05	0.00497	CbGpPWpGaD
Mesalazine—CHUK—Signaling by Interleukins—IL1RN—ankylosing spondylitis	8.51e-05	0.00492	CbGpPWpGaD
Mesalazine—IKBKB—p75(NTR)-mediated signaling—MMP3—ankylosing spondylitis	8.4e-05	0.00486	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—IL1R2—ankylosing spondylitis	8.39e-05	0.00485	CbGpPWpGaD
Mesalazine—CHUK—B Cell Receptor Signaling Pathway—CD79A—ankylosing spondylitis	8.14e-05	0.00471	CbGpPWpGaD
Mesalazine—CHUK—EBV LMP1 signaling—TNF—ankylosing spondylitis	7.99e-05	0.00462	CbGpPWpGaD
Mesalazine—CHUK—Canonical NF-kappaB pathway—TNF—ankylosing spondylitis	7.99e-05	0.00462	CbGpPWpGaD
Mesalazine—IKBKB—Toll-like Receptor Signaling Pathway—IL12B—ankylosing spondylitis	7.9e-05	0.00457	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by Interleukins—IL1RN—ankylosing spondylitis	7.71e-05	0.00446	CbGpPWpGaD
Mesalazine—PPARG—RXR and RAR heterodimerization with other nuclear receptor—TNF—ankylosing spondylitis	7.71e-05	0.00446	CbGpPWpGaD
Mesalazine—MPO—Vitamin B12 Metabolism—TNF—ankylosing spondylitis	7.7e-05	0.00445	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—IL1R2—ankylosing spondylitis	7.61e-05	0.0044	CbGpPWpGaD
Mesalazine—IKBKB—Type II diabetes mellitus—TNF—ankylosing spondylitis	7.5e-05	0.00434	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—KIR3DL1—ankylosing spondylitis	7.46e-05	0.00431	CbGpPWpGaD
Mesalazine—IKBKB—B Cell Receptor Signaling Pathway—CD79A—ankylosing spondylitis	7.38e-05	0.00427	CbGpPWpGaD
Mesalazine—IKBKB—EBV LMP1 signaling—TNF—ankylosing spondylitis	7.24e-05	0.00419	CbGpPWpGaD
Mesalazine—IKBKB—Canonical NF-kappaB pathway—TNF—ankylosing spondylitis	7.24e-05	0.00419	CbGpPWpGaD
Mesalazine—PTGS2—Fluticasone Propionate—Methylprednisolone—ankylosing spondylitis	7.17e-05	0.0957	CbGdCrCtD
Mesalazine—CHUK—TCR Signaling Pathway—IL1A—ankylosing spondylitis	7.09e-05	0.0041	CbGpPWpGaD
Mesalazine—PTGS2—Fluticasone Propionate—Betamethasone—ankylosing spondylitis	7.06e-05	0.0942	CbGdCrCtD
Mesalazine—PTGS2—Fluticasone Propionate—Dexamethasone—ankylosing spondylitis	7.06e-05	0.0942	CbGdCrCtD
Mesalazine—PTGS1—Overview of nanoparticle effects—TNF—ankylosing spondylitis	6.94e-05	0.00402	CbGpPWpGaD
Mesalazine—PTGS2—Fluticasone Propionate—Triamcinolone—ankylosing spondylitis	6.9e-05	0.0921	CbGdCrCtD
Mesalazine—CHUK—Regulation of toll-like receptor signaling pathway—IL12B—ankylosing spondylitis	6.81e-05	0.00394	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—KIR3DL1—ankylosing spondylitis	6.77e-05	0.00391	CbGpPWpGaD
Mesalazine—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—ankylosing spondylitis	6.68e-05	0.00386	CbGpPWpGaD
Mesalazine—CHUK—DAP12 interactions—HLA-C—ankylosing spondylitis	6.6e-05	0.00381	CbGpPWpGaD
Mesalazine—IKBKB—TCR Signaling Pathway—IL1A—ankylosing spondylitis	6.42e-05	0.00372	CbGpPWpGaD
Mesalazine—MPO—Folate Metabolism—TNF—ankylosing spondylitis	6.27e-05	0.00362	CbGpPWpGaD
Mesalazine—IKBKB—Regulation of toll-like receptor signaling pathway—IL12B—ankylosing spondylitis	6.17e-05	0.00357	CbGpPWpGaD
Mesalazine—CHUK—Signaling by Interleukins—IL1A—ankylosing spondylitis	6.12e-05	0.00354	CbGpPWpGaD
Mesalazine—CHUK—HIV-1 Nef: Negative effector of Fas and TNF-alpha—TNF—ankylosing spondylitis	5.98e-05	0.00346	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by Interleukins—IL1A—ankylosing spondylitis	5.55e-05	0.00321	CbGpPWpGaD
Mesalazine—PTGS2—Overview of nanoparticle effects—TNF—ankylosing spondylitis	5.51e-05	0.00319	CbGpPWpGaD
Mesalazine—CHUK—MyD88:Mal cascade initiated on plasma membrane—TLR4—ankylosing spondylitis	5.48e-05	0.00317	CbGpPWpGaD
Mesalazine—CHUK—MyD88-independent cascade—TLR4—ankylosing spondylitis	5.26e-05	0.00304	CbGpPWpGaD
Mesalazine—CHUK—Toll-like Receptor Signaling Pathway—TLR4—ankylosing spondylitis	5.14e-05	0.00297	CbGpPWpGaD
Mesalazine—MPO—Selenium Micronutrient Network—TNF—ankylosing spondylitis	4.98e-05	0.00288	CbGpPWpGaD
Mesalazine—IKBKB—MyD88:Mal cascade initiated on plasma membrane—TLR4—ankylosing spondylitis	4.97e-05	0.00288	CbGpPWpGaD
Mesalazine—CHUK—TWEAK Signaling Pathway—TNF—ankylosing spondylitis	4.93e-05	0.00285	CbGpPWpGaD
Mesalazine—IKBKB—MyD88-independent cascade—TLR4—ankylosing spondylitis	4.77e-05	0.00276	CbGpPWpGaD
Mesalazine—CHUK—Activated TLR4 signalling—TLR4—ankylosing spondylitis	4.73e-05	0.00274	CbGpPWpGaD
Mesalazine—ALOX5—Selenium Micronutrient Network—TNF—ankylosing spondylitis	4.7e-05	0.00272	CbGpPWpGaD
Mesalazine—IKBKB—Toll-like Receptor Signaling Pathway—TLR4—ankylosing spondylitis	4.66e-05	0.00269	CbGpPWpGaD
Mesalazine—CHUK—B Cell Activation—CD79A—ankylosing spondylitis	4.66e-05	0.00269	CbGpPWpGaD
Mesalazine—CHUK—TNF receptor signaling pathway —TNF—ankylosing spondylitis	4.59e-05	0.00265	CbGpPWpGaD
Mesalazine—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—ankylosing spondylitis	4.57e-05	0.00264	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—HLA-C—ankylosing spondylitis	4.57e-05	0.00264	CbGpPWpGaD
Mesalazine—CHUK—Immune System—KIR3DL1—ankylosing spondylitis	4.53e-05	0.00262	CbGpPWpGaD
Mesalazine—PTGS1—Selenium Micronutrient Network—CRP—ankylosing spondylitis	4.5e-05	0.0026	CbGpPWpGaD
Mesalazine—IKBKB—TWEAK Signaling Pathway—TNF—ankylosing spondylitis	4.47e-05	0.00259	CbGpPWpGaD
Mesalazine—CHUK—Toll Like Receptor 4 (TLR4) Cascade—TLR4—ankylosing spondylitis	4.45e-05	0.00257	CbGpPWpGaD
Mesalazine—IKBKB—Activated TLR4 signalling—TLR4—ankylosing spondylitis	4.29e-05	0.00248	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—ERAP1—ankylosing spondylitis	4.29e-05	0.00248	CbGpPWpGaD
Mesalazine—IKBKB—B Cell Activation—CD79A—ankylosing spondylitis	4.22e-05	0.00244	CbGpPWpGaD
Mesalazine—IKBKB—TNF receptor signaling pathway —TNF—ankylosing spondylitis	4.16e-05	0.00241	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—HLA-C—ankylosing spondylitis	4.14e-05	0.0024	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—KIR3DL1—ankylosing spondylitis	4.1e-05	0.00237	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—CARD9—ankylosing spondylitis	4.08e-05	0.00236	CbGpPWpGaD
Mesalazine—IKBKB—Toll Like Receptor 4 (TLR4) Cascade—TLR4—ankylosing spondylitis	4.04e-05	0.00233	CbGpPWpGaD
Mesalazine—CHUK—Regulation of toll-like receptor signaling pathway—TLR4—ankylosing spondylitis	4.01e-05	0.00232	CbGpPWpGaD
Mesalazine—CHUK—Cardiac Hypertrophic Response—TNF—ankylosing spondylitis	3.98e-05	0.0023	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—IL1RN—ankylosing spondylitis	3.97e-05	0.0023	CbGpPWpGaD
Mesalazine—CHUK—Toll-Like Receptors Cascades—TLR4—ankylosing spondylitis	3.97e-05	0.00229	CbGpPWpGaD
Mesalazine—CHUK—DAP12 interactions—HLA-B—ankylosing spondylitis	3.9e-05	0.00226	CbGpPWpGaD
Mesalazine—IKBKB—MAPK Signaling Pathway—IL1A—ankylosing spondylitis	3.9e-05	0.00225	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—ERAP1—ankylosing spondylitis	3.89e-05	0.00225	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—CARD9—ankylosing spondylitis	3.7e-05	0.00214	CbGpPWpGaD
Mesalazine—IKBKB—Regulation of toll-like receptor signaling pathway—TLR4—ankylosing spondylitis	3.64e-05	0.0021	CbGpPWpGaD
Mesalazine—IKBKB—Cardiac Hypertrophic Response—TNF—ankylosing spondylitis	3.61e-05	0.00208	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—IL1RN—ankylosing spondylitis	3.6e-05	0.00208	CbGpPWpGaD
Mesalazine—IKBKB—Toll-Like Receptors Cascades—TLR4—ankylosing spondylitis	3.6e-05	0.00208	CbGpPWpGaD
Mesalazine—PTGS2—Selenium Micronutrient Network—CRP—ankylosing spondylitis	3.57e-05	0.00207	CbGpPWpGaD
Mesalazine—PPARG—Signaling events mediated by HDAC Class I—TNF—ankylosing spondylitis	3.49e-05	0.00202	CbGpPWpGaD
Mesalazine—PTGS2—Spinal Cord Injury—IL1A—ankylosing spondylitis	3.38e-05	0.00195	CbGpPWpGaD
Mesalazine—PPARG—Transcriptional regulation of white adipocyte differentiation—TNF—ankylosing spondylitis	3.24e-05	0.00187	CbGpPWpGaD
Mesalazine—CHUK—Disease—ANTXR2—ankylosing spondylitis	3.17e-05	0.00183	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—IL1A—ankylosing spondylitis	2.86e-05	0.00165	CbGpPWpGaD
Mesalazine—CHUK—Apoptosis—TNF—ankylosing spondylitis	2.83e-05	0.00164	CbGpPWpGaD
Mesalazine—CHUK—MicroRNAs in cardiomyocyte hypertrophy—TNF—ankylosing spondylitis	2.83e-05	0.00164	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IL1R2—ankylosing spondylitis	2.74e-05	0.00159	CbGpPWpGaD
Mesalazine—PTGS2—Aryl Hydrocarbon Receptor—TNF—ankylosing spondylitis	2.72e-05	0.00157	CbGpPWpGaD
Mesalazine—PTGS2—Spinal Cord Injury—TLR4—ankylosing spondylitis	2.71e-05	0.00157	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—HLA-B—ankylosing spondylitis	2.7e-05	0.00156	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—B3GNT2—ankylosing spondylitis	2.69e-05	0.00156	CbGpPWpGaD
Mesalazine—CHUK—TNF alpha Signaling Pathway—TNF—ankylosing spondylitis	2.63e-05	0.00152	CbGpPWpGaD
Mesalazine—CHUK—Immune System—ERAP1—ankylosing spondylitis	2.6e-05	0.0015	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—IL1A—ankylosing spondylitis	2.59e-05	0.0015	CbGpPWpGaD
Mesalazine—IKBKB—MicroRNAs in cardiomyocyte hypertrophy—TNF—ankylosing spondylitis	2.57e-05	0.00149	CbGpPWpGaD
Mesalazine—IKBKB—Apoptosis—TNF—ankylosing spondylitis	2.57e-05	0.00149	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—HLA-C—ankylosing spondylitis	2.56e-05	0.00148	CbGpPWpGaD
Mesalazine—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—ankylosing spondylitis	2.54e-05	0.00147	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—HLA-A—ankylosing spondylitis	2.5e-05	0.00145	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IL1R2—ankylosing spondylitis	2.49e-05	0.00144	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—HLA-C—ankylosing spondylitis	2.46e-05	0.00142	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—HLA-B—ankylosing spondylitis	2.45e-05	0.00142	CbGpPWpGaD
Mesalazine—CHUK—Toll-like Receptor Signaling Pathway—TNF—ankylosing spondylitis	2.43e-05	0.0014	CbGpPWpGaD
Mesalazine—IKBKB—TNF alpha Signaling Pathway—TNF—ankylosing spondylitis	2.39e-05	0.00138	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CARD9—ankylosing spondylitis	2.38e-05	0.00137	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—ERAP1—ankylosing spondylitis	2.36e-05	0.00136	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—HLA-C—ankylosing spondylitis	2.32e-05	0.00134	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—HLA-A—ankylosing spondylitis	2.27e-05	0.00131	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—HLA-C—ankylosing spondylitis	2.23e-05	0.00129	CbGpPWpGaD
Mesalazine—Infection—Methylprednisolone—ankylosing spondylitis	2.21e-05	0.00112	CcSEcCtD
Mesalazine—Haematuria—Methotrexate—ankylosing spondylitis	2.2e-05	0.00112	CcSEcCtD
Mesalazine—IKBKB—Toll-like Receptor Signaling Pathway—TNF—ankylosing spondylitis	2.2e-05	0.00127	CbGpPWpGaD
Mesalazine—Shock—Triamcinolone—ankylosing spondylitis	2.2e-05	0.00111	CcSEcCtD
Mesalazine—Insomnia—Prednisolone—ankylosing spondylitis	2.2e-05	0.00111	CcSEcCtD
Mesalazine—Alopecia—Prednisone—ankylosing spondylitis	2.19e-05	0.00111	CcSEcCtD
Mesalazine—Shock—Methylprednisolone—ankylosing spondylitis	2.19e-05	0.00111	CcSEcCtD
Mesalazine—Hepatobiliary disease—Methotrexate—ankylosing spondylitis	2.19e-05	0.00111	CcSEcCtD
Mesalazine—Nervous system disorder—Methylprednisolone—ankylosing spondylitis	2.19e-05	0.00111	CcSEcCtD
Mesalazine—Loss of consciousness—Dexamethasone—ankylosing spondylitis	2.18e-05	0.0011	CcSEcCtD
Mesalazine—Loss of consciousness—Betamethasone—ankylosing spondylitis	2.18e-05	0.0011	CcSEcCtD
Mesalazine—Epistaxis—Methotrexate—ankylosing spondylitis	2.18e-05	0.0011	CcSEcCtD
Mesalazine—Paraesthesia—Prednisolone—ankylosing spondylitis	2.18e-05	0.0011	CcSEcCtD
Mesalazine—Tachycardia—Triamcinolone—ankylosing spondylitis	2.18e-05	0.0011	CcSEcCtD
Mesalazine—Mental disorder—Prednisone—ankylosing spondylitis	2.18e-05	0.0011	CcSEcCtD
Mesalazine—Tachycardia—Methylprednisolone—ankylosing spondylitis	2.17e-05	0.0011	CcSEcCtD
Mesalazine—Skin disorder—Methylprednisolone—ankylosing spondylitis	2.16e-05	0.0011	CcSEcCtD
Mesalazine—Erythema—Prednisone—ankylosing spondylitis	2.16e-05	0.00109	CcSEcCtD
Mesalazine—Hyperhidrosis—Triamcinolone—ankylosing spondylitis	2.16e-05	0.00109	CcSEcCtD
Mesalazine—Agranulocytosis—Methotrexate—ankylosing spondylitis	2.16e-05	0.00109	CcSEcCtD
Mesalazine—IKBKB—Immune System—CARD9—ankylosing spondylitis	2.16e-05	0.00125	CbGpPWpGaD
Mesalazine—Hyperhidrosis—Methylprednisolone—ankylosing spondylitis	2.15e-05	0.00109	CcSEcCtD
Mesalazine—Hypertension—Betamethasone—ankylosing spondylitis	2.14e-05	0.00109	CcSEcCtD
Mesalazine—Hypertension—Dexamethasone—ankylosing spondylitis	2.14e-05	0.00109	CcSEcCtD
Mesalazine—PPARG—Adipogenesis—TNF—ankylosing spondylitis	2.13e-05	0.00123	CbGpPWpGaD
Mesalazine—Myalgia—Betamethasone—ankylosing spondylitis	2.11e-05	0.00107	CcSEcCtD
Mesalazine—Myalgia—Dexamethasone—ankylosing spondylitis	2.11e-05	0.00107	CcSEcCtD
Mesalazine—Anxiety—Dexamethasone—ankylosing spondylitis	2.11e-05	0.00107	CcSEcCtD
Mesalazine—Anxiety—Betamethasone—ankylosing spondylitis	2.11e-05	0.00107	CcSEcCtD
Mesalazine—Discomfort—Betamethasone—ankylosing spondylitis	2.09e-05	0.00106	CcSEcCtD
Mesalazine—Discomfort—Dexamethasone—ankylosing spondylitis	2.09e-05	0.00106	CcSEcCtD
Mesalazine—Haemoglobin—Methotrexate—ankylosing spondylitis	2.09e-05	0.00106	CcSEcCtD
Mesalazine—Hypotension—Methylprednisolone—ankylosing spondylitis	2.08e-05	0.00105	CcSEcCtD
Mesalazine—Pain—Prednisolone—ankylosing spondylitis	2.08e-05	0.00105	CcSEcCtD
Mesalazine—Hepatitis—Methotrexate—ankylosing spondylitis	2.08e-05	0.00105	CcSEcCtD
Mesalazine—Haemorrhage—Methotrexate—ankylosing spondylitis	2.08e-05	0.00105	CcSEcCtD
Mesalazine—Pharyngitis—Methotrexate—ankylosing spondylitis	2.06e-05	0.00104	CcSEcCtD
Mesalazine—Urinary tract disorder—Methotrexate—ankylosing spondylitis	2.05e-05	0.00104	CcSEcCtD
Mesalazine—Vision blurred—Prednisone—ankylosing spondylitis	2.04e-05	0.00103	CcSEcCtD
Mesalazine—PTGS1—Selenium Micronutrient Network—TNF—ankylosing spondylitis	2.04e-05	0.00118	CbGpPWpGaD
Mesalazine—Urethral disorder—Methotrexate—ankylosing spondylitis	2.03e-05	0.00103	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Triamcinolone—ankylosing spondylitis	2.03e-05	0.00103	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Methylprednisolone—ankylosing spondylitis	2.03e-05	0.00103	CcSEcCtD
Mesalazine—Anaphylactic shock—Dexamethasone—ankylosing spondylitis	2.03e-05	0.00103	CcSEcCtD
Mesalazine—Oedema—Dexamethasone—ankylosing spondylitis	2.03e-05	0.00103	CcSEcCtD
Mesalazine—Oedema—Betamethasone—ankylosing spondylitis	2.03e-05	0.00103	CcSEcCtD
Mesalazine—Anaphylactic shock—Betamethasone—ankylosing spondylitis	2.03e-05	0.00103	CcSEcCtD
Mesalazine—Insomnia—Triamcinolone—ankylosing spondylitis	2.02e-05	0.00102	CcSEcCtD
Mesalazine—Insomnia—Methylprednisolone—ankylosing spondylitis	2.02e-05	0.00102	CcSEcCtD
Mesalazine—Infection—Betamethasone—ankylosing spondylitis	2.01e-05	0.00102	CcSEcCtD
Mesalazine—Infection—Dexamethasone—ankylosing spondylitis	2.01e-05	0.00102	CcSEcCtD
Mesalazine—Ill-defined disorder—Prednisone—ankylosing spondylitis	2.01e-05	0.00102	CcSEcCtD
Mesalazine—Paraesthesia—Triamcinolone—ankylosing spondylitis	2.01e-05	0.00102	CcSEcCtD
Mesalazine—Feeling abnormal—Prednisolone—ankylosing spondylitis	2e-05	0.00101	CcSEcCtD
Mesalazine—Paraesthesia—Methylprednisolone—ankylosing spondylitis	2e-05	0.00101	CcSEcCtD
Mesalazine—Anaemia—Prednisone—ankylosing spondylitis	2e-05	0.00101	CcSEcCtD
Mesalazine—Shock—Dexamethasone—ankylosing spondylitis	1.99e-05	0.00101	CcSEcCtD
Mesalazine—Shock—Betamethasone—ankylosing spondylitis	1.99e-05	0.00101	CcSEcCtD
Mesalazine—Dyspnoea—Triamcinolone—ankylosing spondylitis	1.99e-05	0.00101	CcSEcCtD
Mesalazine—Nervous system disorder—Dexamethasone—ankylosing spondylitis	1.99e-05	0.00101	CcSEcCtD
Mesalazine—Nervous system disorder—Betamethasone—ankylosing spondylitis	1.99e-05	0.00101	CcSEcCtD
Mesalazine—Thrombocytopenia—Dexamethasone—ankylosing spondylitis	1.98e-05	0.001	CcSEcCtD
Mesalazine—Thrombocytopenia—Betamethasone—ankylosing spondylitis	1.98e-05	0.001	CcSEcCtD
Mesalazine—Tachycardia—Betamethasone—ankylosing spondylitis	1.98e-05	0.001	CcSEcCtD
Mesalazine—Tachycardia—Dexamethasone—ankylosing spondylitis	1.98e-05	0.001	CcSEcCtD
Mesalazine—Angioedema—Prednisone—ankylosing spondylitis	1.98e-05	0.001	CcSEcCtD
Mesalazine—Dyspepsia—Triamcinolone—ankylosing spondylitis	1.97e-05	0.000995	CcSEcCtD
Mesalazine—Erythema multiforme—Methotrexate—ankylosing spondylitis	1.96e-05	0.000993	CcSEcCtD
Mesalazine—Dyspepsia—Methylprednisolone—ankylosing spondylitis	1.96e-05	0.000993	CcSEcCtD
Mesalazine—Hyperhidrosis—Betamethasone—ankylosing spondylitis	1.96e-05	0.000992	CcSEcCtD
Mesalazine—Hyperhidrosis—Dexamethasone—ankylosing spondylitis	1.96e-05	0.000992	CcSEcCtD
Mesalazine—Malaise—Prednisone—ankylosing spondylitis	1.95e-05	0.000987	CcSEcCtD
Mesalazine—Vertigo—Prednisone—ankylosing spondylitis	1.94e-05	0.000983	CcSEcCtD
Mesalazine—Eye disorder—Methotrexate—ankylosing spondylitis	1.94e-05	0.000982	CcSEcCtD
Mesalazine—Syncope—Prednisone—ankylosing spondylitis	1.94e-05	0.000981	CcSEcCtD
Mesalazine—Tinnitus—Methotrexate—ankylosing spondylitis	1.94e-05	0.00098	CcSEcCtD
Mesalazine—Anorexia—Betamethasone—ankylosing spondylitis	1.93e-05	0.000978	CcSEcCtD
Mesalazine—Anorexia—Dexamethasone—ankylosing spondylitis	1.93e-05	0.000978	CcSEcCtD
Mesalazine—Urticaria—Prednisolone—ankylosing spondylitis	1.93e-05	0.000977	CcSEcCtD
Mesalazine—Cardiac disorder—Methotrexate—ankylosing spondylitis	1.93e-05	0.000975	CcSEcCtD
Mesalazine—Fatigue—Triamcinolone—ankylosing spondylitis	1.93e-05	0.000975	CcSEcCtD
Mesalazine—Fatigue—Methylprednisolone—ankylosing spondylitis	1.92e-05	0.000972	CcSEcCtD
Mesalazine—Pain—Triamcinolone—ankylosing spondylitis	1.91e-05	0.000967	CcSEcCtD
Mesalazine—Loss of consciousness—Prednisone—ankylosing spondylitis	1.9e-05	0.000962	CcSEcCtD
Mesalazine—CHUK—Regulation of toll-like receptor signaling pathway—TNF—ankylosing spondylitis	1.89e-05	0.0011	CbGpPWpGaD
Mesalazine—Hypotension—Dexamethasone—ankylosing spondylitis	1.89e-05	0.000958	CcSEcCtD
Mesalazine—Hypotension—Betamethasone—ankylosing spondylitis	1.89e-05	0.000958	CcSEcCtD
Mesalazine—Angiopathy—Methotrexate—ankylosing spondylitis	1.88e-05	0.000953	CcSEcCtD
Mesalazine—CHUK—Adaptive Immune System—CD79A—ankylosing spondylitis	1.88e-05	0.00109	CbGpPWpGaD
Mesalazine—PTGS2—Disease—ANTXR2—ankylosing spondylitis	1.88e-05	0.00108	CbGpPWpGaD
Mesalazine—Immune system disorder—Methotrexate—ankylosing spondylitis	1.87e-05	0.000949	CcSEcCtD
Mesalazine—Mediastinal disorder—Methotrexate—ankylosing spondylitis	1.87e-05	0.000947	CcSEcCtD
Mesalazine—Hypertension—Prednisone—ankylosing spondylitis	1.87e-05	0.000945	CcSEcCtD
Mesalazine—CHUK—Disease—B3GNT2—ankylosing spondylitis	1.87e-05	0.00108	CbGpPWpGaD
Mesalazine—Chills—Methotrexate—ankylosing spondylitis	1.86e-05	0.000943	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Betamethasone—ankylosing spondylitis	1.85e-05	0.000934	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Dexamethasone—ankylosing spondylitis	1.85e-05	0.000934	CcSEcCtD
Mesalazine—Arthralgia—Prednisone—ankylosing spondylitis	1.84e-05	0.000932	CcSEcCtD
Mesalazine—Myalgia—Prednisone—ankylosing spondylitis	1.84e-05	0.000932	CcSEcCtD
Mesalazine—Feeling abnormal—Triamcinolone—ankylosing spondylitis	1.84e-05	0.000932	CcSEcCtD
Mesalazine—Feeling abnormal—Methylprednisolone—ankylosing spondylitis	1.84e-05	0.000929	CcSEcCtD
Mesalazine—Anxiety—Prednisone—ankylosing spondylitis	1.83e-05	0.000929	CcSEcCtD
Mesalazine—Alopecia—Methotrexate—ankylosing spondylitis	1.83e-05	0.000928	CcSEcCtD
Mesalazine—Insomnia—Betamethasone—ankylosing spondylitis	1.83e-05	0.000928	CcSEcCtD
Mesalazine—Insomnia—Dexamethasone—ankylosing spondylitis	1.83e-05	0.000928	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ankylosing spondylitis	1.83e-05	0.000925	CcSEcCtD
Mesalazine—Gastrointestinal pain—Methylprednisolone—ankylosing spondylitis	1.82e-05	0.000922	CcSEcCtD
Mesalazine—Paraesthesia—Betamethasone—ankylosing spondylitis	1.82e-05	0.000921	CcSEcCtD
Mesalazine—Paraesthesia—Dexamethasone—ankylosing spondylitis	1.82e-05	0.000921	CcSEcCtD
Mesalazine—Discomfort—Prednisone—ankylosing spondylitis	1.82e-05	0.000921	CcSEcCtD
Mesalazine—Mental disorder—Methotrexate—ankylosing spondylitis	1.82e-05	0.000921	CcSEcCtD
Mesalazine—Erythema—Methotrexate—ankylosing spondylitis	1.81e-05	0.000915	CcSEcCtD
Mesalazine—Hypersensitivity—Prednisolone—ankylosing spondylitis	1.79e-05	0.000906	CcSEcCtD
Mesalazine—Dyspepsia—Betamethasone—ankylosing spondylitis	1.78e-05	0.000903	CcSEcCtD
Mesalazine—Dyspepsia—Dexamethasone—ankylosing spondylitis	1.78e-05	0.000903	CcSEcCtD
Mesalazine—Urticaria—Triamcinolone—ankylosing spondylitis	1.77e-05	0.000898	CcSEcCtD
Mesalazine—Urticaria—Methylprednisolone—ankylosing spondylitis	1.77e-05	0.000896	CcSEcCtD
Mesalazine—Dysgeusia—Methotrexate—ankylosing spondylitis	1.77e-05	0.000896	CcSEcCtD
Mesalazine—Body temperature increased—Triamcinolone—ankylosing spondylitis	1.77e-05	0.000894	CcSEcCtD
Mesalazine—Anaphylactic shock—Prednisone—ankylosing spondylitis	1.76e-05	0.000893	CcSEcCtD
Mesalazine—Oedema—Prednisone—ankylosing spondylitis	1.76e-05	0.000893	CcSEcCtD
Mesalazine—Abdominal pain—Methylprednisolone—ankylosing spondylitis	1.76e-05	0.000892	CcSEcCtD
Mesalazine—Decreased appetite—Dexamethasone—ankylosing spondylitis	1.76e-05	0.000892	CcSEcCtD
Mesalazine—Decreased appetite—Betamethasone—ankylosing spondylitis	1.76e-05	0.000892	CcSEcCtD
Mesalazine—Infection—Prednisone—ankylosing spondylitis	1.75e-05	0.000887	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Betamethasone—ankylosing spondylitis	1.75e-05	0.000886	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Dexamethasone—ankylosing spondylitis	1.75e-05	0.000886	CcSEcCtD
Mesalazine—Back pain—Methotrexate—ankylosing spondylitis	1.75e-05	0.000885	CcSEcCtD
Mesalazine—Fatigue—Betamethasone—ankylosing spondylitis	1.75e-05	0.000884	CcSEcCtD
Mesalazine—Fatigue—Dexamethasone—ankylosing spondylitis	1.75e-05	0.000884	CcSEcCtD
Mesalazine—Shock—Prednisone—ankylosing spondylitis	1.74e-05	0.000879	CcSEcCtD
Mesalazine—Pain—Dexamethasone—ankylosing spondylitis	1.73e-05	0.000877	CcSEcCtD
Mesalazine—Pain—Betamethasone—ankylosing spondylitis	1.73e-05	0.000877	CcSEcCtD
Mesalazine—Nervous system disorder—Prednisone—ankylosing spondylitis	1.73e-05	0.000876	CcSEcCtD
Mesalazine—Tachycardia—Prednisone—ankylosing spondylitis	1.72e-05	0.000872	CcSEcCtD
Mesalazine—IKBKB—Regulation of toll-like receptor signaling pathway—TNF—ankylosing spondylitis	1.72e-05	0.000993	CbGpPWpGaD
Mesalazine—Skin disorder—Prednisone—ankylosing spondylitis	1.71e-05	0.000868	CcSEcCtD
Mesalazine—Hyperhidrosis—Prednisone—ankylosing spondylitis	1.71e-05	0.000864	CcSEcCtD
Mesalazine—Vision blurred—Methotrexate—ankylosing spondylitis	1.7e-05	0.000862	CcSEcCtD
Mesalazine—IKBKB—Adaptive Immune System—CD79A—ankylosing spondylitis	1.7e-05	0.000984	CbGpPWpGaD
Mesalazine—Anorexia—Prednisone—ankylosing spondylitis	1.68e-05	0.000851	CcSEcCtD
Mesalazine—Ill-defined disorder—Methotrexate—ankylosing spondylitis	1.68e-05	0.000849	CcSEcCtD
Mesalazine—Anaemia—Methotrexate—ankylosing spondylitis	1.67e-05	0.000845	CcSEcCtD
Mesalazine—Feeling abnormal—Dexamethasone—ankylosing spondylitis	1.67e-05	0.000845	CcSEcCtD
Mesalazine—Feeling abnormal—Betamethasone—ankylosing spondylitis	1.67e-05	0.000845	CcSEcCtD
Mesalazine—PPARG—Metabolism—B3GNT2—ankylosing spondylitis	1.66e-05	0.000963	CbGpPWpGaD
Mesalazine—Gastrointestinal pain—Dexamethasone—ankylosing spondylitis	1.66e-05	0.000839	CcSEcCtD
Mesalazine—Gastrointestinal pain—Betamethasone—ankylosing spondylitis	1.66e-05	0.000839	CcSEcCtD
Mesalazine—Hypersensitivity—Triamcinolone—ankylosing spondylitis	1.65e-05	0.000833	CcSEcCtD
Mesalazine—Hypersensitivity—Methylprednisolone—ankylosing spondylitis	1.64e-05	0.000831	CcSEcCtD
Mesalazine—Malaise—Methotrexate—ankylosing spondylitis	1.63e-05	0.000825	CcSEcCtD
Mesalazine—Vertigo—Methotrexate—ankylosing spondylitis	1.62e-05	0.000822	CcSEcCtD
Mesalazine—Leukopenia—Methotrexate—ankylosing spondylitis	1.62e-05	0.000819	CcSEcCtD
Mesalazine—PTGS2—Selenium Micronutrient Network—TNF—ankylosing spondylitis	1.62e-05	0.000935	CbGpPWpGaD
Mesalazine—Urticaria—Dexamethasone—ankylosing spondylitis	1.61e-05	0.000815	CcSEcCtD
Mesalazine—Urticaria—Betamethasone—ankylosing spondylitis	1.61e-05	0.000815	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Prednisone—ankylosing spondylitis	1.61e-05	0.000814	CcSEcCtD
Mesalazine—Dizziness—Prednisolone—ankylosing spondylitis	1.61e-05	0.000813	CcSEcCtD
Mesalazine—Asthenia—Triamcinolone—ankylosing spondylitis	1.6e-05	0.000811	CcSEcCtD
Mesalazine—Body temperature increased—Betamethasone—ankylosing spondylitis	1.6e-05	0.000811	CcSEcCtD
Mesalazine—Abdominal pain—Betamethasone—ankylosing spondylitis	1.6e-05	0.000811	CcSEcCtD
Mesalazine—Body temperature increased—Dexamethasone—ankylosing spondylitis	1.6e-05	0.000811	CcSEcCtD
Mesalazine—Abdominal pain—Dexamethasone—ankylosing spondylitis	1.6e-05	0.000811	CcSEcCtD
Mesalazine—Asthenia—Methylprednisolone—ankylosing spondylitis	1.6e-05	0.000809	CcSEcCtD
Mesalazine—Insomnia—Prednisone—ankylosing spondylitis	1.6e-05	0.000808	CcSEcCtD
Mesalazine—Paraesthesia—Prednisone—ankylosing spondylitis	1.58e-05	0.000802	CcSEcCtD
Mesalazine—Pruritus—Triamcinolone—ankylosing spondylitis	1.58e-05	0.0008	CcSEcCtD
Mesalazine—Cough—Methotrexate—ankylosing spondylitis	1.58e-05	0.000798	CcSEcCtD
Mesalazine—Pruritus—Methylprednisolone—ankylosing spondylitis	1.58e-05	0.000798	CcSEcCtD
Mesalazine—Dyspepsia—Prednisone—ankylosing spondylitis	1.55e-05	0.000786	CcSEcCtD
Mesalazine—Myalgia—Methotrexate—ankylosing spondylitis	1.54e-05	0.000779	CcSEcCtD
Mesalazine—Chest pain—Methotrexate—ankylosing spondylitis	1.54e-05	0.000779	CcSEcCtD
Mesalazine—Arthralgia—Methotrexate—ankylosing spondylitis	1.54e-05	0.000779	CcSEcCtD
Mesalazine—Decreased appetite—Prednisone—ankylosing spondylitis	1.53e-05	0.000776	CcSEcCtD
Mesalazine—Rash—Prednisolone—ankylosing spondylitis	1.53e-05	0.000775	CcSEcCtD
Mesalazine—CHUK—Adaptive Immune System—CD40LG—ankylosing spondylitis	1.53e-05	0.000885	CbGpPWpGaD
Mesalazine—Dermatitis—Prednisolone—ankylosing spondylitis	1.53e-05	0.000774	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—ankylosing spondylitis	1.53e-05	0.000773	CcSEcCtD
Mesalazine—Diarrhoea—Methylprednisolone—ankylosing spondylitis	1.52e-05	0.000772	CcSEcCtD
Mesalazine—Fatigue—Prednisone—ankylosing spondylitis	1.52e-05	0.00077	CcSEcCtD
Mesalazine—Headache—Prednisolone—ankylosing spondylitis	1.52e-05	0.00077	CcSEcCtD
Mesalazine—Discomfort—Methotrexate—ankylosing spondylitis	1.52e-05	0.000769	CcSEcCtD
Mesalazine—CHUK—Innate Immune System—HLA-B—ankylosing spondylitis	1.52e-05	0.000876	CbGpPWpGaD
Mesalazine—Constipation—Prednisone—ankylosing spondylitis	1.51e-05	0.000764	CcSEcCtD
Mesalazine—CHUK—Immune System—HLA-C—ankylosing spondylitis	1.49e-05	0.000863	CbGpPWpGaD
Mesalazine—Confusional state—Methotrexate—ankylosing spondylitis	1.49e-05	0.000753	CcSEcCtD
Mesalazine—Dizziness—Triamcinolone—ankylosing spondylitis	1.48e-05	0.000748	CcSEcCtD
Mesalazine—IKBKB—MAPK Signaling Pathway—TNF—ankylosing spondylitis	1.48e-05	0.000853	CbGpPWpGaD
Mesalazine—Anaphylactic shock—Methotrexate—ankylosing spondylitis	1.47e-05	0.000747	CcSEcCtD
Mesalazine—Dizziness—Methylprednisolone—ankylosing spondylitis	1.47e-05	0.000746	CcSEcCtD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	1.47e-05	0.000849	CbGpPWpGaD
Mesalazine—Infection—Methotrexate—ankylosing spondylitis	1.47e-05	0.000742	CcSEcCtD
Mesalazine—CHUK—Adaptive Immune System—HLA-B—ankylosing spondylitis	1.46e-05	0.000842	CbGpPWpGaD
Mesalazine—Feeling abnormal—Prednisone—ankylosing spondylitis	1.45e-05	0.000736	CcSEcCtD
Mesalazine—Asthenia—Betamethasone—ankylosing spondylitis	1.45e-05	0.000736	CcSEcCtD
Mesalazine—Asthenia—Dexamethasone—ankylosing spondylitis	1.45e-05	0.000736	CcSEcCtD
Mesalazine—Nervous system disorder—Methotrexate—ankylosing spondylitis	1.45e-05	0.000732	CcSEcCtD
Mesalazine—Thrombocytopenia—Methotrexate—ankylosing spondylitis	1.44e-05	0.000731	CcSEcCtD
Mesalazine—Gastrointestinal pain—Prednisone—ankylosing spondylitis	1.44e-05	0.00073	CcSEcCtD
Mesalazine—Nausea—Prednisolone—ankylosing spondylitis	1.44e-05	0.00073	CcSEcCtD
Mesalazine—Pruritus—Dexamethasone—ankylosing spondylitis	1.43e-05	0.000726	CcSEcCtD
Mesalazine—Pruritus—Betamethasone—ankylosing spondylitis	1.43e-05	0.000726	CcSEcCtD
Mesalazine—Skin disorder—Methotrexate—ankylosing spondylitis	1.43e-05	0.000725	CcSEcCtD
Mesalazine—Hyperhidrosis—Methotrexate—ankylosing spondylitis	1.43e-05	0.000722	CcSEcCtD
Mesalazine—Vomiting—Triamcinolone—ankylosing spondylitis	1.42e-05	0.000719	CcSEcCtD
Mesalazine—Vomiting—Methylprednisolone—ankylosing spondylitis	1.42e-05	0.000717	CcSEcCtD
Mesalazine—Rash—Triamcinolone—ankylosing spondylitis	1.41e-05	0.000713	CcSEcCtD
Mesalazine—Dermatitis—Triamcinolone—ankylosing spondylitis	1.41e-05	0.000712	CcSEcCtD
Mesalazine—Anorexia—Methotrexate—ankylosing spondylitis	1.41e-05	0.000712	CcSEcCtD
Mesalazine—Rash—Methylprednisolone—ankylosing spondylitis	1.4e-05	0.000711	CcSEcCtD
Mesalazine—Dermatitis—Methylprednisolone—ankylosing spondylitis	1.4e-05	0.00071	CcSEcCtD
Mesalazine—Urticaria—Prednisone—ankylosing spondylitis	1.4e-05	0.00071	CcSEcCtD
Mesalazine—Headache—Triamcinolone—ankylosing spondylitis	1.4e-05	0.000708	CcSEcCtD
Mesalazine—Headache—Methylprednisolone—ankylosing spondylitis	1.4e-05	0.000707	CcSEcCtD
Mesalazine—Abdominal pain—Prednisone—ankylosing spondylitis	1.39e-05	0.000706	CcSEcCtD
Mesalazine—Body temperature increased—Prednisone—ankylosing spondylitis	1.39e-05	0.000706	CcSEcCtD
Mesalazine—IKBKB—Adaptive Immune System—CD40LG—ankylosing spondylitis	1.39e-05	0.000802	CbGpPWpGaD
Mesalazine—Diarrhoea—Betamethasone—ankylosing spondylitis	1.39e-05	0.000702	CcSEcCtD
Mesalazine—Diarrhoea—Dexamethasone—ankylosing spondylitis	1.39e-05	0.000702	CcSEcCtD
Mesalazine—Hypotension—Methotrexate—ankylosing spondylitis	1.38e-05	0.000698	CcSEcCtD
Mesalazine—IKBKB—Innate Immune System—HLA-B—ankylosing spondylitis	1.37e-05	0.000795	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—HLA-C—ankylosing spondylitis	1.35e-05	0.000783	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—HLA-A—ankylosing spondylitis	1.35e-05	0.00078	CbGpPWpGaD
Mesalazine—Musculoskeletal discomfort—Methotrexate—ankylosing spondylitis	1.34e-05	0.00068	CcSEcCtD
Mesalazine—Dizziness—Betamethasone—ankylosing spondylitis	1.34e-05	0.000678	CcSEcCtD
Mesalazine—Dizziness—Dexamethasone—ankylosing spondylitis	1.34e-05	0.000678	CcSEcCtD
Mesalazine—CHUK—Innate Immune System—CRP—ankylosing spondylitis	1.34e-05	0.000775	CbGpPWpGaD
Mesalazine—Insomnia—Methotrexate—ankylosing spondylitis	1.33e-05	0.000675	CcSEcCtD
Mesalazine—Nausea—Triamcinolone—ankylosing spondylitis	1.33e-05	0.000671	CcSEcCtD
Mesalazine—Paraesthesia—Methotrexate—ankylosing spondylitis	1.32e-05	0.00067	CcSEcCtD
Mesalazine—Nausea—Methylprednisolone—ankylosing spondylitis	1.32e-05	0.00067	CcSEcCtD
Mesalazine—IKBKB—Adaptive Immune System—HLA-B—ankylosing spondylitis	1.32e-05	0.000763	CbGpPWpGaD
Mesalazine—Dyspnoea—Methotrexate—ankylosing spondylitis	1.31e-05	0.000666	CcSEcCtD
Mesalazine—Somnolence—Methotrexate—ankylosing spondylitis	1.31e-05	0.000664	CcSEcCtD
Mesalazine—Hypersensitivity—Prednisone—ankylosing spondylitis	1.3e-05	0.000658	CcSEcCtD
Mesalazine—Dyspepsia—Methotrexate—ankylosing spondylitis	1.3e-05	0.000657	CcSEcCtD
Mesalazine—CHUK—Immune System—IL1RN—ankylosing spondylitis	1.3e-05	0.00075	CbGpPWpGaD
Mesalazine—Vomiting—Betamethasone—ankylosing spondylitis	1.29e-05	0.000652	CcSEcCtD
Mesalazine—Vomiting—Dexamethasone—ankylosing spondylitis	1.29e-05	0.000652	CcSEcCtD
Mesalazine—CHUK—Innate Immune System—TLR4—ankylosing spondylitis	1.28e-05	0.000743	CbGpPWpGaD
Mesalazine—Decreased appetite—Methotrexate—ankylosing spondylitis	1.28e-05	0.000649	CcSEcCtD
Mesalazine—PTGS2—Spinal Cord Injury—TNF—ankylosing spondylitis	1.28e-05	0.000739	CbGpPWpGaD
Mesalazine—Rash—Dexamethasone—ankylosing spondylitis	1.28e-05	0.000647	CcSEcCtD
Mesalazine—Rash—Betamethasone—ankylosing spondylitis	1.28e-05	0.000647	CcSEcCtD
Mesalazine—Dermatitis—Betamethasone—ankylosing spondylitis	1.28e-05	0.000646	CcSEcCtD
Mesalazine—Dermatitis—Dexamethasone—ankylosing spondylitis	1.28e-05	0.000646	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Methotrexate—ankylosing spondylitis	1.27e-05	0.000644	CcSEcCtD
Mesalazine—Fatigue—Methotrexate—ankylosing spondylitis	1.27e-05	0.000644	CcSEcCtD
Mesalazine—Headache—Dexamethasone—ankylosing spondylitis	1.27e-05	0.000643	CcSEcCtD
Mesalazine—Headache—Betamethasone—ankylosing spondylitis	1.27e-05	0.000643	CcSEcCtD
Mesalazine—Asthenia—Prednisone—ankylosing spondylitis	1.27e-05	0.000641	CcSEcCtD
Mesalazine—Pain—Methotrexate—ankylosing spondylitis	1.26e-05	0.000638	CcSEcCtD
Mesalazine—Pruritus—Prednisone—ankylosing spondylitis	1.25e-05	0.000632	CcSEcCtD
Mesalazine—IKBKB—Adaptive Immune System—HLA-A—ankylosing spondylitis	1.22e-05	0.000707	CbGpPWpGaD
Mesalazine—Feeling abnormal—Methotrexate—ankylosing spondylitis	1.22e-05	0.000615	CcSEcCtD
Mesalazine—IKBKB—Innate Immune System—CRP—ankylosing spondylitis	1.21e-05	0.000702	CbGpPWpGaD
Mesalazine—Diarrhoea—Prednisone—ankylosing spondylitis	1.21e-05	0.000611	CcSEcCtD
Mesalazine—Gastrointestinal pain—Methotrexate—ankylosing spondylitis	1.21e-05	0.00061	CcSEcCtD
Mesalazine—Nausea—Dexamethasone—ankylosing spondylitis	1.2e-05	0.000609	CcSEcCtD
Mesalazine—Nausea—Betamethasone—ankylosing spondylitis	1.2e-05	0.000609	CcSEcCtD
Mesalazine—IKBKB—Immune System—IL1RN—ankylosing spondylitis	1.18e-05	0.00068	CbGpPWpGaD
Mesalazine—Urticaria—Methotrexate—ankylosing spondylitis	1.17e-05	0.000593	CcSEcCtD
Mesalazine—Dizziness—Prednisone—ankylosing spondylitis	1.17e-05	0.000591	CcSEcCtD
Mesalazine—PTGS1—Metabolism—B3GNT2—ankylosing spondylitis	1.17e-05	0.000674	CbGpPWpGaD
Mesalazine—Body temperature increased—Methotrexate—ankylosing spondylitis	1.17e-05	0.00059	CcSEcCtD
Mesalazine—Abdominal pain—Methotrexate—ankylosing spondylitis	1.17e-05	0.00059	CcSEcCtD
Mesalazine—IKBKB—Innate Immune System—TLR4—ankylosing spondylitis	1.16e-05	0.000673	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CD79A—ankylosing spondylitis	1.14e-05	0.000658	CbGpPWpGaD
Mesalazine—Vomiting—Prednisone—ankylosing spondylitis	1.12e-05	0.000568	CcSEcCtD
Mesalazine—Rash—Prednisone—ankylosing spondylitis	1.11e-05	0.000563	CcSEcCtD
Mesalazine—Dermatitis—Prednisone—ankylosing spondylitis	1.11e-05	0.000563	CcSEcCtD
Mesalazine—Headache—Prednisone—ankylosing spondylitis	1.11e-05	0.00056	CcSEcCtD
Mesalazine—PTGS2—Disease—B3GNT2—ankylosing spondylitis	1.11e-05	0.000639	CbGpPWpGaD
Mesalazine—Hypersensitivity—Methotrexate—ankylosing spondylitis	1.09e-05	0.00055	CcSEcCtD
Mesalazine—Asthenia—Methotrexate—ankylosing spondylitis	1.06e-05	0.000536	CcSEcCtD
Mesalazine—Nausea—Prednisone—ankylosing spondylitis	1.05e-05	0.000531	CcSEcCtD
Mesalazine—Pruritus—Methotrexate—ankylosing spondylitis	1.04e-05	0.000528	CcSEcCtD
Mesalazine—IKBKB—Immune System—CD79A—ankylosing spondylitis	1.03e-05	0.000597	CbGpPWpGaD
Mesalazine—Diarrhoea—Methotrexate—ankylosing spondylitis	1.01e-05	0.000511	CcSEcCtD
Mesalazine—Dizziness—Methotrexate—ankylosing spondylitis	9.75e-06	0.000494	CcSEcCtD
Mesalazine—Vomiting—Methotrexate—ankylosing spondylitis	9.38e-06	0.000475	CcSEcCtD
Mesalazine—CHUK—Immune System—IL1A—ankylosing spondylitis	9.33e-06	0.00054	CbGpPWpGaD
Mesalazine—Rash—Methotrexate—ankylosing spondylitis	9.3e-06	0.000471	CcSEcCtD
Mesalazine—Dermatitis—Methotrexate—ankylosing spondylitis	9.29e-06	0.00047	CcSEcCtD
Mesalazine—CHUK—Immune System—CD40LG—ankylosing spondylitis	9.28e-06	0.000537	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—B3GNT2—ankylosing spondylitis	9.26e-06	0.000535	CbGpPWpGaD
Mesalazine—Headache—Methotrexate—ankylosing spondylitis	9.24e-06	0.000468	CcSEcCtD
Mesalazine—CHUK—Signaling Pathways—PTGER4—ankylosing spondylitis	8.96e-06	0.000518	CbGpPWpGaD
Mesalazine—CHUK—Immune System—HLA-B—ankylosing spondylitis	8.83e-06	0.00051	CbGpPWpGaD
Mesalazine—Nausea—Methotrexate—ankylosing spondylitis	8.76e-06	0.000443	CcSEcCtD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	8.7e-06	0.000503	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IL1A—ankylosing spondylitis	8.46e-06	0.000489	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CD40LG—ankylosing spondylitis	8.42e-06	0.000487	CbGpPWpGaD
Mesalazine—CHUK—Immune System—HLA-A—ankylosing spondylitis	8.18e-06	0.000473	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PTGER4—ankylosing spondylitis	8.13e-06	0.00047	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—HLA-B—ankylosing spondylitis	8e-06	0.000463	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CRP—ankylosing spondylitis	7.8e-06	0.000451	CbGpPWpGaD
Mesalazine—CHUK—Disease—HLA-A—ankylosing spondylitis	7.55e-06	0.000437	CbGpPWpGaD
Mesalazine—CHUK—Immune System—TLR4—ankylosing spondylitis	7.48e-06	0.000433	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—HLA-A—ankylosing spondylitis	7.42e-06	0.000429	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—TNF—ankylosing spondylitis	7.31e-06	0.000423	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CRP—ankylosing spondylitis	7.08e-06	0.000409	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—TLR4—ankylosing spondylitis	6.78e-06	0.000392	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MMP3—ankylosing spondylitis	6.38e-06	0.000369	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MMP3—ankylosing spondylitis	5.79e-06	0.000335	CbGpPWpGaD
Mesalazine—PTGS2—Disease—HLA-A—ankylosing spondylitis	4.47e-06	0.000259	CbGpPWpGaD
